Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1992 Feb;36(2):299–307. doi: 10.1128/aac.36.2.299

Relationship of pharmacokinetics and drug distribution in tissue to increased safety of amphotericin B colloidal dispersion in dogs.

R M Fielding 1, A W Singer 1, L H Wang 1, S Babbar 1, L S Guo 1
PMCID: PMC188430  PMID: 1605595

Abstract

The safety, pharmacokinetics, and distribution in tissue of an amphotericin B (AmB)-cholesteryl sulfate colloidal dispersion (ABCD) were compared with those of micellar amphotericin B-deoxycholate (m-AmB). Dogs received 14 daily injections of ABCD (0.6 to 10 mg/kg of body weight per day) or m-AmB (0.6 mg/kg/day). Safety was evaluated by monitoring body weight, hematology, clinical chemistry, and urinalysis during the study and by microscopic examination of tissues at the time of necropsy (day 16). AmB concentrations in plasma were measured in some groups on days 1, 7, and 14 and in necropsy tissue samples. ABCD produced a spectrum of toxic effects in the kidneys, gut, and liver similar to those of m-AmB, but ABCD was eightfold safer than m-AmB. The highest tolerated dose of ABCD (5.0 mg/kg/day) produced effects similar to those of m-AmB (0.6 mg/kg/day). ABCD produced lower concentrations in plasma than an equal dose of m-AmB did. Clearances on days 7 and 14 were higher for ABCD (304 and 295 ml/h.kg) than they were for m-AmB (67 and 53 ml/h.kg). Concentrations in plasma reached steady state after ABCD administration, but they increased after repeated dosing with m-AmB. Diurnal fluctuations in AmB concentrations in plasma were observed 4 to 8 h after the time of dosing. ABCD resulted in lower AmB concentrations in tissue than m-AmB did, except in the reticuloendothelial system. Up to 90% of AmB administered as ABCD was recovered from the liver and spleen on day 16. Reduced drug levels in the kidneys and gut correlated with reduced indications of toxicity in these organs after ABCD administration. Although ABCD increased concentrations of AmB in the reticuloendothelial system, increased toxicity was not observed in these organs.

Full text

PDF
299

Images in this article

301Image
on p.301

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahmad I., Sarkar A. K., Bachhawat B. K. Liposomal amphotericin-B in the control of experimental aspergillosis in mice: Part I--Relative therapeutic efficacy of free and liposomal amphotericin-B. Indian J Biochem Biophys. 1989 Dec;26(6):351–356. [PubMed] [Google Scholar]
  2. Brajtburg J., Powderly W. G., Kobayashi G. S., Medoff G. Amphotericin B: delivery systems. Antimicrob Agents Chemother. 1990 Mar;34(3):381–384. doi: 10.1128/aac.34.3.381. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Ching M. S., Raymond K., Bury R. W., Mashford M. L., Morgan D. J. Absorption of orally administered amphotericin B lozenges. Br J Clin Pharmacol. 1983 Jul;16(1):106–108. doi: 10.1111/j.1365-2125.1983.tb02152.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Collette N., van der Auwera P., Lopez A. P., Heymans C., Meunier F. Tissue concentrations and bioactivity of amphotericin B in cancer patients treated with amphotericin B-deoxycholate. Antimicrob Agents Chemother. 1989 Mar;33(3):362–368. doi: 10.1128/aac.33.3.362. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Craven P. C., Ludden T. M., Drutz D. J., Rogers W., Haegele K. A., Skrdlant H. B. Excretion pathways of amphotericin B. J Infect Dis. 1979 Sep;140(3):329–341. doi: 10.1093/infdis/140.3.329. [DOI] [PubMed] [Google Scholar]
  6. Ellens H., Rustum Y., Mayhew E., Ledesma E. Distribution and metabolism of lipsome-encapsulated and free 1-beta-D-arabinofuranosylcytosine (Ara-C) in dog and mouse tissues. J Pharmacol Exp Ther. 1982 Aug;222(2):324–330. [PubMed] [Google Scholar]
  7. Fielding R. M., Smith P. C., Wang L. H., Porter J., Guo L. S. Comparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation to rats. Antimicrob Agents Chemother. 1991 Jun;35(6):1208–1213. doi: 10.1128/aac.35.6.1208. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Graybill J. R., Craven P. C., Taylor R. L., Williams D. M., Magee W. E. Treatment of murine cryptococcosis with liposome-associated amphotericin B. J Infect Dis. 1982 May;145(5):748–752. doi: 10.1093/infdis/145.2.748. [DOI] [PubMed] [Google Scholar]
  9. Hoeprich P. D., Huston A. C., Wolfe B. M. Toxicity of amphotericins on chronic administration to mongrel dogs. Diagn Microbiol Infect Dis. 1985 Jan;3(1):47–58. doi: 10.1016/0732-8893(85)90066-5. [DOI] [PubMed] [Google Scholar]
  10. Kim H., Loebenberg D., Marco A., Symchowicz S., Lin C. Comparative pharmacokinetics of Sch 28191 and amphotericin B in mice, rats, dogs, and cynomolgus monkeys. Antimicrob Agents Chemother. 1984 Oct;26(4):446–449. doi: 10.1128/aac.26.4.446. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Lopez-Berestein G., Fainstein V., Hopfer R., Mehta K., Sullivan M. P., Keating M., Rosenblum M. G., Mehta R., Luna M., Hersh E. M. Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study. J Infect Dis. 1985 Apr;151(4):704–710. doi: 10.1093/infdis/151.4.704. [DOI] [PubMed] [Google Scholar]
  12. Lopez-Berestein G., Rosenblum M. G., Mehta R. Altered tissue distribution of amphotericin B by liposomal encapsulation: comparison of normal mice to mice infected with Candida albicans. Cancer Drug Deliv. 1984 Summer;1(3):199–205. doi: 10.1089/cdd.1984.1.199. [DOI] [PubMed] [Google Scholar]
  13. Massa T., Sinha D. P., Frantz J. D., Filipek M. E., Weglein R. C., Steinberg S. A., McGrath J. T., Murphy B. F., Szot R. J., Black H. E. Subchronic toxicity studies of N-D-ornithyl amphotericin B methyl ester in dogs and rats. Fundam Appl Toxicol. 1985 Aug;5(4):737–753. doi: 10.1016/0272-0590(85)90198-8. [DOI] [PubMed] [Google Scholar]
  14. Patterson T. F., Andriole V. T. The role of liposomal amphotericin B in the treatment of systemic fungal infections. Eur J Cancer Clin Oncol. 1989;25 (Suppl 2):S63–S68. [PubMed] [Google Scholar]
  15. Patterson T. F., Miniter P., Dijkstra J., Szoka F. C., Jr, Ryan J. L., Andriole V. T. Treatment of experimental invasive aspergillosis with novel amphotericin B/cholesterol-sulfate complexes. J Infect Dis. 1989 Apr;159(4):717–724. doi: 10.1093/infdis/159.4.717. [DOI] [PubMed] [Google Scholar]
  16. Vadiei K., Lopez-Berestein G., Luke D. R. Disposition and toxicity of amphotericin-B in the hyperlipidemic Zucker rat model. Int J Obes. 1990 Jun;14(6):465–472. [PubMed] [Google Scholar]
  17. Wasan K. M., Vadiei K., Lopez-Berestein G., Luke D. R. Pharmacokinetics, tissue distribution, and toxicity of free and liposomal amphotericin B in diabetic rats. J Infect Dis. 1990 Mar;161(3):562–566. doi: 10.1093/infdis/161.3.562. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES